Gene expression signature associated with survival in advanced ovarian cancer

Feb 03, 2009

A new study published this week in the open-access journal PLoS Medicine identifies molecular pathways associated with outcomes in ovarian cancer. Currently, outcomes following diagnosis of ovarian cancer are very poor, with up to 65-70% of women dying within five years of diagnosis.

Anne Crijns and her colleagues from the University of Groningen in the Netherlands aimed to find out whether the expression levels of particular genes were associated with overall survival in ovarian cancer. The researchers initially studied a series of tissue samples, obtained during surgery to remove cancerous tissue from 157 consecutive patients seen at the University Medical Center Groningen. Analysis of the samples identified 86 genes which correlated with overall survival in the women. The researchers were then able to confirm, for 57 of the 86 genes, that these were also correlated with survival in a second, entirely separate dataset. Specific genes, and pathways, were identified which provide specific targets around which researchers might be able to design potential therapies in future.

For example, Crijns and colleagues find high expression of a gene encoding a FK506 binding protein, FKBP7, is associated with poor prognosis. This protein can be targeted with existing drugs, the mTOR inhibitors. Another implication of the work discussed by the researchers is the use of this expression signature to identify women who are at greater risk of relapse, and thus potentially personalize treatment. However, as the authors acknowledge, such implications are still some way off. It would be important to carry out prospective studies in order to show that the signature performs effectively in a clinical setting.

The new study is discussed in an expert commentary by Simon Gayther and Kate Lawrenson of University College London, who were not involved in the study.

Citation: Crijns APG, Fehrmann RSN, de Jong S, Gerbens F, Meersma GJ, et al. (2009) Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med 6(2): e1000024. doi:10.1371/journal.pmed.1000024
medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.1000024

Source: Public Library of Science

Explore further: New study finds that proton therapy has fewer side effects in esophageal cancer patients

Related Stories

Lightbulb using graphene is to go on sale this year

Mar 30, 2015

The BBC reported on Saturday that a graphene bulb is set for shops, to go on sale this year. UK developers said their graphene bulb will be the first commercially viable consumer product using the super- ...

Steroid links fat accumulation with egg development

Mar 19, 2015

Nutrition and metabolism are closely linked with reproductive health. Several reproductive disorders including polycystic ovary syndrome, amenorrhea, and ovarian cancer have been linked to malnutrition, diabetes, ...

Recommended for you

Vortex device makes for better cancer treatments

2 hours ago

A South Australian invention, responsible for unboiling an egg, has been used to produce a four-fold increase in efficacy of carboplatin, a commonly used drug for ovarian, lung and other cancer. ...

Using healthy skin to identify cancer's origins

22 hours ago

Normal skin contains an unexpectedly high number of cancer-associated mutations, according to a study published in Science. The findings illuminate the first steps cells take towards becoming a cancer and de ...

Gender differences in receipt of end-of-life care

22 hours ago

(HealthDay)—There are gender differences in receipt of end-of-life (EoL) care among terminally ill cancer patients, with male patients more likely to receive intensive care unit (ICU) care, according to ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.